Navigation Links
DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
Date:4/10/2013

titute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor StatementAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com; or contact

Jeffrey A. Bacha
President & CEO
DelMar Pharmaceuticals
(604) 629-5989

-or-

Booke & Company Investor Relations
admin@bookeandco.com

 


'/>"/>
SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
2. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
3. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
4. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
5. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
6. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
7. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
8. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
9. Global Pharmacy Automation Market 2012-2016 with McKesson Corp., ScriptPro LLC, Parata Systems LLC Dominating
10. Global Pharmaceutical Leader Chooses Acsis Enterprise Serialization Management Suite to Achieve e-Pedigree Compliance
11. Zosano Pharma, Inc. Announces Key Strategic Hire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Calif. , Nov. 20, 2014  Edwards Lifesciences ... in the science of heart valves and hemodynamic monitoring, ... giving in 2014 to support a strong launch of ... Matters , and to improve the global communities where ... 2014, Edwards, global corporate giving will exceed $8 million, ...
(Date:11/21/2014)... , Nov. 20, 2014 /CNW Telbec/ - KLOX Technologies ... the following appointments: Todd Martensen ... the newly created role of Chief Commercial Officer, to ... using topical photoconverter gel for the treatment of chronic ... traumatic wounds, recently approved in Europe ...
(Date:11/21/2014)... Fla. , Nov. 20, 2014   Coqui ... become the first U.S. commercial producer of Molybdenum-99 (Mo-99), ... contract with INVAP to design its Medical ... Mo-99 is the parent isotope of Technetium-99, ... procedures worldwide. In 2012, Congress passed legislation making it ...
Breaking Medicine Technology:Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... 2010 United Seating & Mobility (USM) , one ... excited to announce today that it has finalized a transaction ... The transaction applies to Fridley, MN serving the greater ... and Appleton, WI; RehabTECH will continue to operate its Illinois ...
... Dec, 2, 2010 SRI International, an independent ... it is collaborating with PhenoMatriX (PMX), a biotechnology ... drugs such as cisplatin and related analogues are ... have served as major weapons against solid tumors ...
Cached Medicine Technology:SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 2SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 3SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 4
(Date:11/22/2014)... Greenville, Sc (PRWEB) November 23, 2014 ... officially opened its doors in the downtown Greenville area. ... of Downtown Greenville , decided to open her own ... such amazing results with the patients. , AlignLife ... the proper tools. With a focus on chiropractic care ...
(Date:11/22/2014)... 2014 PrettyTailor , an outstanding ... new big promotion. Customers can buy new dresses at ... can visit its website. , As a matter of ... dresses. It mainly provides four types of wedding outfits, ... flower girl dresses. It also provides a variety of ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 A classic black ... of the most famous dress suppliers, has unveiled its new ... new dresses are now offered at a big discount, up ... special offer. , The new black prom dresses, made ... order to meet the needs of all customers, the company ...
(Date:11/22/2014)... 2014 BambooFlooringChina.com is a famous ... proudly released its new collection of bamboo mats ; ... to 29% off. , According to the sales ... grass, making it a highly renewable resource. Their bamboo mats ... mixing color which comes from natural bamboo with caramel bamboo ...
(Date:11/22/2014)... New York, NY (PRWEB) November 22, 2014 ... Australia’s Therapeutics Goods Administration (TGA) approved it for ... Glutathione was approved and listed within the Therapeutic ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione ... Chem, a biotech specialist that sources and imports ...
Breaking Medicine News(10 mins):Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... Childhood cancer survivors diagnosed later with non-melanoma skin cancer ... tumor within 15 years, according to research led by ... percent of survivors in this Childhood Cancer Survivor Study ... skin cancer developed another more aggressive cancer within 15 ...
... June 2010 Elsevier, a world-leading healthcare and ... an agreement with Tarrytown, New York based InfoDesk ... for pharmaceutical and life science companies. The ... technological know-how paves the way for the development ...
... available in German . Early detection is ... every lump turns out to be a malignant tumor. To ... a biopsy and examine the removed tissue under the microscope. ... but also highly time consuming. Research scientists at the Fraunhofer ...
... 8, 2010) A University of Minnesota study definitively shows ... an increased life expectancy. The research is published in the ... The findings stem from the Program on Surgical Control ... at the University of Minnesota in 1975. Researchers evaluated 838 ...
... unique study with sunitinib suggest that it might be ... to treat HIV-positive cancer patients to achieve therapeutic benefit. ... treat their HIV, much more or considerably less chemotherapy ... NCI-supported AIDS Malignancy Consortium (AMC). The trial design ...
... 2010 The Institute for Research in Immunology and ... a new research funding model that brings together the ... accelerate the discovery of new anti-cancer therapeutics. Inspired by ... athletes at the Vancouver Winter Olympics, B2Discovery,s mission is ...
Cached Medicine News:Health News:Non-melanoma skin cancer may help identify survivors at increased risk for future cancers 2Health News:Elsevier and InfoDesk collaborate to co-develop federated drug pipeline intelligence solution 2Health News:Detecting tumors faster 2Health News:Consortium seeks best treatment for HIV-positive cancer patients 2Health News:Consortium seeks best treatment for HIV-positive cancer patients 3Health News:B2Discovery: Entrepreneurs and researchers join forces to conquer cancer 2
... Activins are polypeptide hormones which belong ... superfamily. The TGF- superfamily is a ... which control many aspects of development, ... Other members incude TGF-s, bone morphogenetic ...
... also known as bone Gla protein, is ... is a major component of the noncollagenous ... osteoblasts in bone, with a small amount ... chondrocytes [1]. During bone formation, newly synthesized ...
... Insulin-like growth factor binding protein-2 (IGFBP-2) is ... have been proposed) which specifically bind and ... The binding affinity of IGFBP-2 for IGF-II ... for IGF-I [1], suggesting a role in ...
... suppress the secretion of FSH (follicle stimulating ... two distinct chains, or subunits (alpha and ... the alpha-subunit and betaA-subunit. Inhibin B consists ... dimeric forms of the molecule, containing both ...
Medicine Products: